Leqembi was approved by the Food and Drug Administration (FDA) in January, 2023, and is indicated for the treatment of patients with mild/early Alzheimer’s dementia. Due to promising results, the FDA used an accelerated pathway that allows drugs to be released for use before all clinical studies have been completed.
If you have unsatisfactory sleep, you are not alone.
Insomnia is a sleep disorder characterized by trouble falling asleep initially, waking up during the night, or waking earlier than desired. These sleep patterns can lead to daytime impairments including fatigue, irritability, depressed mood, problems with concentration and memory and increased accidents and mistakes.
Sleep disorders affect up to 70 million Americans every year, and insomnia symptoms affect 33-50% of adults. Chronic insomnia, defined as sleep difficulties occurring at least 3 days per week for 3 months or longer, is found in 10-15% of adult Americans.
Researchers at the University of Oklahoma Stephenson Cancer Center in Oklahoma City recently announced the first clinical trial of a new anticancer drug dubbed OK-1. This trial, which will be led by the drug’s creator, Doris Benbrook PhD., will include women with advanced stage ovarian, endometrial and cervical cancers.
